Descripción del proyecto
Un injerto de bioingeniería para mejorar la regeneración ósea
La regeneración ósea mediante injertos artificiales debe servir de guía para el crecimiento de nuevo hueso y favorecer su integración en el tejido circundante. Para facilitar este proceso y mejorar la regeneración ósea, el proyecto financiado con fondos europeos HEALIKICK trabaja en el desarrollo de un método combinatorio innovador, que utiliza un material de injerto granular con un recubrimiento de gran capacidad osteógena sembrado con células madre mesenquimales adiposas osteógenas prediferenciadas. Los científicos validarán primero este método a través de estudios preclínicos en aras de presentar los desarrollos reglamentarios y técnicos necesarios para el ensayo clínico. También llevarán a cabo las actividades de optimización y desarrollo necesarias para adaptar este método al tratamiento de alteraciones en huesos largos.
Objetivo
Disruptive technologies for bone regeneration must be able to tackle complex fracture environments which have developed into non-union bone defects. These types of fracture are common and increasingly prevalent when considering the rise in osteoporosis cases. Bioengineered bone graft systems need to be able to guide the regrowth of new bone into substantial voids and therefore implants pre-seeded with mineralising cells are of significant clinical interest. We will implement a surgical co-administration of two robust technologies 1) a granular graft material with a highly osteogenic coating that presents relevant biologics very efficiently and 2) pre-differentiated osteogenic adipose mesenchymal stromal cells (MSCs) that together will underpin efficient bone regeneration. Within the project we aim to take these two technologies into GMP and ISO rated manufacture as required for any clinical therapy. We will then implement these therapies in pre-clinical studies to obtain efficacy and safety data to support a full clinical trial application. The novel technologies will be developed into a new medical device and a new cellular therapy with pre-clinical validation for their co-administration. This modular application of two highly advanced therapies is itself highly novel in terms of clinical strategy and by the end of the project we aim to have made the required regulatory and technical developments to submit them for clinical trial. In parallel to the core therapy we will expand the therapeutic pipeline by replacing the granular graft with 3D printed polymeric scaffold, again including including a highly osteogeneic coating, as a carrier for the cell therapy. Targeting even larger bone defects, this scaffold will be co-administered with the cellular therapy in pre-clinical efficacy studies.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2019-Single-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
G12 8QQ Glasgow
Reino Unido